Micro Market Research
+1-888-502-0539
US/CAN Toll Free

You are here :   Home     Healthcare     Pharmaceuticals     Drug formulations    
Real Time Market Research & Industry Analysis - MicroMarketMonitor

Global Acute myeloid leukemia (AML) Market Research Report

  • Report Code: AC 1000
  • Publish Date: Upcoming
  
Description
Table of Contents
Customer Intelligence
Summary
Inquiry Before Buying Ask for Discount
Acute myeloid leukemia (AML) and its peer markets - Burkitt lymphoma, T-cell Lymphoma, Non-Hodgkin lymphoma, Hodgkin lymphoma, Hairy-cell leukemia, Chronic myeloid leukemia (CML), Lymphoplasmacytic lymphoma, Multiple myeloma, Acute lymphoblastic leukemia (ALL) and 3 other type markets - adds up to total Haematopoietic and lymphoid tissues Cancers market.

Acute myeloid leukemia (AML) can be segmented by Submarkets, Geographies, Companies and Products. Submarkets of this market are Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems (CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Chromatography Instruments, Next Generation Sequencing (NGS), Proteomics, Marketed Drugs (AML) and Pipeline Drugs (AML). Geographies of this market are USA, Canada, United Kingdom, Germany, France, Italy, Spain and Japan. Companies of this market are Clavis Pharma ASA, Teva Pharmaceuticals, Inc (cephalon), Eisai Co.,Ltd., Sunesis Pharmaceuticals, Inc., Genzyme Corporation, Ambit Biosciences Corporation and Celgene Corporation. Products of this market are Graspa, DFP-10917 and BP-100-1.01.

 

Key Questions Answered

  • What are market estimates and forecasts; which of Acute myeloid leukemia (AML) markets are doing well and which are not?
  • What is the competitive landscape; How companies like Clavis Pharma ASA, Teva Pharmaceuticals, Inc (cephalon) and Eisai Co.,Ltd. doing in Acute myeloid leukemia (AML)?
  •  

    What makes our report unique?

    • This reports provides most granular segmentation on Chromatography, E-Clinical Trial Solutions, Wireless Health and Clinical Trial Management Systems (CTMS).
    • This report provides market sizing and forecast for the Acute myeloid leukemia (AML) market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
    • The report provides deep dive competitive landscape covering the top players such as Clavis Pharma ASA, Teva Pharmaceuticals, Inc (cephalon), Eisai Co.,Ltd. and Sunesis Pharmaceuticals, Inc..
    • The reports provides benchmarking insight on the top players Clavis Pharma ASA, Teva Pharmaceuticals, Inc (cephalon), Eisai Co.,Ltd. and Sunesis Pharmaceuticals, Inc..
    • The report provide competitive intelligence on Clavis Pharma ASA, Teva Pharmaceuticals, Inc (cephalon), Eisai Co.,Ltd. and Sunesis Pharmaceuticals, Inc..
    •  

      Audience for this report

      • Global Acute myeloid leukemia (AML) companies
      • Manufacturing Companies
      • Traders, distributors, and suppliers
      • Governmental and research organizations
      • Associations and industry bodies
      • Technology providers
      •  

        Top developments

        • FDA approved Dacogen (decitabine) injection
        • Phase Ib study for Vosaroxin
        • Ambit Biosciences and Astellas Pharma Inc. presented Phase II study results for quizartinib (AC220)
        • Dacogen (decitabine) phase III (DACO-016) study started
        • Clavis was awarded a grant of $2.5 million from The Research Council of Norway
        • Eisai and PRISM BioLab Co. Ltd (Yokohama) underwent an agreement
        • Cephalon acquired ChemGenex Pharma
        • Sunesis Pharmaceuticals received a patent (No. 1725233) from European Patent Office (EPO) for vosaroxin
        • Celgene Corporation obtained final appraisal determination from National Institute for Health and Clinical Excellence (NICE) for Vidaza
        • Sunesis Pharmaceuticals received Fast Track designation for Vosaroxin


1 Introduction
1.1 Analyst Insights
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
2 Executive Summary
3 Market Overview
4 By Submarkets
4.1 Chromatography
4.2 E-Clinical Trial Solutions
4.3 Wireless Health
4.4 Clinical Trial Management Systems (CTMS)
4.5 Healthcare IT outsourcing
4.6 Immunoassay
4.7 Digital Pathology
4.8 Chromatography Instruments
4.9 Next Generation Sequencing (NGS)
4.10 Proteomics
4.11 Marketed Drugs (AML)
4.12 Pipeline Drugs (AML)
5 By Products
5.1 Graspa
5.2 DFP-10917
5.3 BP-100-1.01
6 By Geographies
6.1 USA
6.2 Canada
6.3 United Kingdom
6.4 Germany
6.5 France
6.6 Italy
6.7 Spain
6.8 Japan
7 By Companies
7.1 Clavis Pharma ASA
7.2 Teva Pharmaceuticals, Inc (cephalon)
7.3 Eisai Co.,Ltd.
7.4 Sunesis Pharmaceuticals, Inc.
7.5 Genzyme Corporation
7.6 Ambit Biosciences Corporation
7.7 Celgene Corporation

Please fill in the form below to receive a free copy of the Summary of this Report
















Global Acute myeloid leukemia (AML) Market Research Report

* Enter the text from the image to the text box :

refresh captcha
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
PRODUCT TITLE PUBLISHED
Daunorubicin + Cytarabine (For Induction) Daunorubicin + Cytarabine (For Induction)
Daunorubicin + Cytarabine (For Induction) and Graspa, Cytarabine (For...
Upcoming
Cytarabine (For Relapse) Cytarabine (For Relapse)
Cytarabine (For Relapse) and Graspa, Daunorubicin +...
Upcoming
Daunorubicin + Cytarabine (For Elderly) Daunorubicin + Cytarabine (For Elderly)
Daunorubicin + Cytarabine (For Elderly) and Graspa,
Upcoming
VCD Regimen (APL) VCD Regimen (APL)
VCD Regimen (APL) and Graspa, Daunorubicin + Cytarabine...
Upcoming
AVD Regimen (APL) AVD Regimen (APL)
AVD Regimen (APL) and Graspa, Daunorubicin + Cytarabine...
Upcoming
Phase I (AML) Phase I (AML)
Phase I (AML) and Phase II (AML) and Phase III (AML) adds up to total...
Upcoming
Phase II (AML) Phase II (AML)
Phase II (AML) and Phase I (AML) and Phase III (AML) adds up to total...
Upcoming
Phase III (AML) Phase III (AML)
Phase III (AML) and Phase I (AML) and Phase II (AML) adds up to total...
Upcoming
8 of 8 items
8 reports | Show
Connect With Us
US/CAN : +1-888-502-0539